MXC launches new CBD nutraceuticals line: taps multi-billion-dollar market
Specialist medicinal cannabis company, MGC Pharmaceuticals (ASX:MXC), this week launched MGC Nutraceuticals, a new line of CBD and hemp-enhanced vegan products targeting the high-end dietary supplement market.
This new range immediately expands MXC’s consumer product offering into the multi-billion-dollar dietary supplement market with seven new high-end natural vegan products.
This premium product offering is gluten-free, and based on high-grade phytocannabinoids, which have been grown, extracted and processed under MXC’s strict quality control guidelines, alongside natural vegan proteins and vitamins.
The range also meets the EU’s high standards, with health claims complying with EU legislation.
Promoting inner health and well-being, this range includes seven premium products, comprising four supplements and three food grade products in flavours such as forest fruit, blueberry and vanilla.
All of these products have been formulated for daily use, and to promote normal immune system function, improve stress protection, and maintain muscle and bone structure.
MXC is tapping a fruitful and quickly growing market with this new line. Consider that the global nutraceutical market was valued at around US$383.06 billion in 2016 and is expected to expand to some US$56.38 billion by 2022.
Also noteworthy is that MXC’s expansion into this market leverages its existing capabilities, including IP, manufacturing capabilities and marketing distribution, with minimal additional investment.
To accompany the launch, MXC has released a catalogue featuring the entire MGC Nutraceuticals range, which will be available from the newly created online store (to customers in jurisdictions that permit it).
Of course, it should be noted here that MXC is still in its early stages and anything can happen, so investors should seek professional financial advice if considering this stock for their portfolio.
MXC co-founder and CEO, Roby Zomer, said: “MGC’s Nutraceuticals range taps into the large and growing health supplement market, providing a CBD and hemp protein-based range of products to consumers that believe in the health benefits derived from CBD and hemp.
“Our expansion into this complementary market leverages our existing capabilities... meaning we have been able to develop an entirely new range of products for an entirely new market, with minimal additional investment,” Zomer added.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.